Canton Biologics is a biotechnology company specializing in providing bio-pharmaceutical development, manufacturing, and supply chain services for global pharmaceutical enterprises. Established in 2016 and headquartered in China, the company has made significant strides in the biologics industry. It boasts a team of over 300 scientists with extensive experience and a high level of expertise, with over 60% holding advanced degrees.
The company's last investment, a CNY300.00M Series C investment, took place on 13th September 2023 and was led by prominent investors including SDIC Ventures, Taipu Life Sciences Investment, Guangdong Technology Financial Group, and Qianyin Investment. This funding signifies strong support and confidence in the company's potential and progress.
Canton Biologics' offerings include a wide range of services such as Biologics CDMO covering Monoclonal Antibody, Bispecific Antibody, Fusion Protein, Recombinant Protein, and Vaccine, as well as Cell and Gene Therapy (CGT) CDMO, and Global Clinical Supply with capabilities in manufacturing, packaging, storage, and distribution.
The company has also made remarkable advancements in operational efficiency, setting a new industry record by completing the process from DNA to CMC in just 7 months. Additionally, Canton Biologics boasts 13+5 manufacturing lines that comply with China, US, and EU GMP standards, further solidifying its position as a reliable and innovative partner for pharmaceutical development.
In conclusion, Canton Biologics' strong foundation, impressive service offerings, and recent substantial investment point to its potential to become the preferred global Biologics CDMO for Biotech, making it a compelling prospect for venture capital firms seeking opportunities in the biotechnology and manufacturing sectors.
